Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
Tuan VuAndreas MeiselRenato MantegazzaDjillali AnnaneMasahisa KatsunoRasha AguzziAhmed EnayetallahKathleen N BeasleyNishi RampalJames F HowardPublished in: Neurology and therapy (2023)
This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis (MP4 594600 KB).